Associated Papers
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Tsao AS et al.
Jco Precision Oncology, 2025
Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review.
Markota Cagalj A et al.
Journal of Drug Targeting, 2025
Imperatorin Suppresses Aberrant Hedgehog Pathway and Overcomes Smoothened Antagonist Resistance via STAT3 Inhibition.
Wang J et al.
Drug Design, Development and Therapy, 2024
Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.
Hoashi T et al.
International Journal of Molecular Sciences, 2022
Towards Precision Oncology: The Role of Smoothened and Its Variants in Cancer.
Nicheperovich A et al.
Journal of Personalized Medicine, 2022
Sonic Hedgehog Signaling in Cerebellar Development and Cancer.
Wang W et al.
Frontiers in Cell and Developmental Biology, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N et al.
Proteins, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
Menyhárt O et al.
Annals of Clinical and Translational Neurology, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A et al.
Bmc Cancer, 2018
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Krug AK et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2018
Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.
Petrirena GJ et al.
Oncotarget, 2018
Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligand.
Zhang X et al.
Nature Communications, 2017
Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome.
Chaudhary SC et al.
Oncotarget, 2015
Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.
Gururangan S et al.
Pediatric Blood & Cancer, 2015
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ et al.
Cancer Cell, 2015
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX et al.
Cancer Cell, 2015
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S et al.
Molecular Oncology, 2015
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Yamada T et al.
Oncogene, 2013
Matching mice to malignancy: molecular subgroups and models of medulloblastoma.
Lau J et al.
Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery, 2012
Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened.
Tao H et al.
Chemistry & Biology, 2011
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Dijkgraaf GJ et al.
Cancer Research, 2011
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL et al.
Science (new York, N.y.), 2009